Inhaler monitoring company Adherium said that it has signed a deal with Summatix (formerly Charm Informatics) to allow data from Adherium’s Hailie connected inhaler sensors to be accessed through the Summatix medical data platform. Adherium also announced the launch of a new Hailie app for patients and an updated platform for clinicians.
Adherium received OTC clearance for Hailie sensors used with a number of inhalers in the US in July 2018 and launched direct-to-consumer sales in the US the next month.
According to Adherium, the two companies “will develop a roadmap to accelerate the Hailie reimbursement focused rollout in the US, as well as in other key target markets including the UK, the European Union, China and Japan. This strategy will cover both Hailie sensor technology as well as Adherium’s digital software platform.”
Adherium CEO Jeremy Curnock Cook commented, “Adherium is excited to be partnering with Summatix in our continued efforts to deliver transformative asthma/COPD patient care. We are confident that when combined with the Summatix platform capabilities, Adherium’s Hailie solution will deliver significant advantages for patients, caregivers, doctors, and other health care providers in managing these costly diseases.”
Summatix CEO Jeff Gross said, “It will also be a test case for providing US clinicians with the means to access new remote monitoring reimbursement codes, using Summatix’s auditable reports to improve their workflow and deliver better care for their patients.”
Read the Adherium and Summatix press release.
